Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal blend shows promise against COVID-19 in small trial

NCT ID NCT05043324

Disease control Sponsor: Nguyen Thi Trieu, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 4 trial tested a herbal supplement called AntiCov-220 in 82 people with underlying health conditions, including HIV and cancer. The goal was to see if it could prevent and treat COVID-19 by boosting the immune system and fighting the virus. The study compared the supplement to a placebo, but detailed results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AntiCov-220 (a blend of herbal extracts and vitamins)
What this could lead to
If it works, this could offer a way to prevent and treat COVID-19, especially in people with other health conditions.
What could go wrong
This is a small, completed Phase 4 trial with only 82 participants. The results are not yet widely published, and the herbal mixture's effectiveness is uncertain. Some participants had serious conditions like HIV, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

82 people

The number who actually took part.

Started

Feb 2020

Finished

Apr 2022

Lead sponsor

An individual researcher

The lead sponsor is a named person rather than an organisation.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 82 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All patients with underlying medical conditions who have been taking medications for these conditions. * Patients with AIDS, HIV, HBV, HCV, and patients with co-infections. * The cancer patients are stable. * Patients with congenital or acquired immunodeficiency. Exclusion Criteria: * Unstable cancer patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS COVID-19 hepatitis B virus infection hepatitis C virus infection HIV infectious disease stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19

Contacts and locations

Locations

  • Saigon Biopharma Company Limited

    Ho Chi Minh City, 700000, Vietnam

  • Saigon Biopharma LLC

    Wilmington, Delaware, 19801-6601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.